50 Participants Needed

rTMS + Virtual Reality Therapy for Mild Cognitive Impairment

(rTMS+iVCT Trial)

IM
LM
Overseen ByLasi McGhee
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Central Arkansas Veterans Healthcare System
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 2 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores whether combining brain stimulation with virtual reality training can improve thinking abilities and mood in older adults with Mild Cognitive Impairment (MCI). Participants will be divided into groups: one receiving only brain stimulation using rTMS (a non-invasive method that uses magnetic fields to stimulate the brain), another receiving both rTMS and virtual reality cognitive exercises, and a control group with no intervention. It targets individuals diagnosed with MCI, aged 55 or older, who meet specific cognitive criteria. As an unphased trial, this study offers participants a unique opportunity to contribute to innovative research that could enhance cognitive health in older adults.

Will I have to stop taking my current medications?

The trial requires that you stop taking medications known to increase the risk of seizures and ototoxic medications (medications that can damage the ear). If you are on these medications, you may need to stop them to participate.

What prior data suggests that this combination of rTMS and iVCT is safe for individuals with Mild Cognitive Impairment?

Research has shown that repetitive Transcranial Magnetic Stimulation (rTMS) is generally safe for people with Mild Cognitive Impairment (MCI). Studies indicate that rTMS is usually well-tolerated, with serious side effects being rare. Most people experience only minor issues, such as headaches or a tingling sensation on the scalp.

The combination of rTMS with immersive virtual reality cognitive training (iVCT) remains under study. Early research suggests it is safe, but more studies are needed for confirmation. Overall, current evidence on rTMS, especially when used alone, is promising for safety. For those considering joining this study, it appears to be a low-risk option based on current research.12345

Why are researchers excited about this trial?

Researchers are excited about rTMS combined with Virtual Reality Therapy for Mild Cognitive Impairment because it offers a novel, non-invasive approach to brain stimulation that might enhance cognitive function. Unlike traditional medications like cholinesterase inhibitors or memantine, which can have side effects and focus on slowing cognitive decline, rTMS uses magnetic fields to stimulate nerve cells in the brain, potentially improving memory and thinking skills. The addition of immersive Virtual Reality Therapy could further engage and challenge the brain in ways that standard therapies cannot, providing a dual-action approach that both stimulates and exercises cognitive pathways. This combination could offer a promising alternative for those who don't respond well to current treatments.

What evidence suggests that this trial's treatments could be effective for Mild Cognitive Impairment?

Studies have shown that repetitive Transcranial Magnetic Stimulation (rTMS) can improve thinking and memory in people with Mild Cognitive Impairment (MCI). Specifically, research indicates that rTMS led to noticeable improvements in memory and cognitive test scores. In this trial, one group will receive rTMS treatment alone, while another group will receive a combination of rTMS and Virtual Reality cognitive training (iVCT). Early findings suggest that combining rTMS with iVCT might further enhance thinking skills. Using rTMS and virtual reality together has improved memory and other cognitive abilities. Overall, these treatments show promise for boosting brain function in those with MCI.15678

Are You a Good Fit for This Trial?

This trial is for adults over 55 with Mild Cognitive Impairment (MCI) who score at least 18 on the MoCA test. It's not suitable for those with implanted devices, under 55, seizure risks, history of certain neurological issues, or sensitivity to light and sound.

Inclusion Criteria

I am 55 years old or older.
You have previously been diagnosed with Mild Cognitive Impairment.
My mental function score is 18 or higher.

Exclusion Criteria

I or my close family members have had seizures.
You have a history of Tourette's syndrome or currently experience uncontrollable body movements.
I have had a stroke, aneurysm, or brain surgery in the past.
See 11 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

Baseline Assessment

Participants undergo baseline assessment to evaluate cognitive, emotional, and functional abilities

1 week
1 visit (in-person)

Treatment

Participants receive rTMS or rTMS+iVCT treatment for 5 days a week for 2 weeks

2 weeks
10 visits (in-person)

Post-treatment Assessment

Participants repeat testing to assess treatment-related changes

2 weeks
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

3 months
1 visit (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • iVCT
  • rTMS
Trial Overview The study tests if brain stimulation (rTMS) combined with virtual reality cognitive training (iVCT) can improve cognition and mood in MCI patients more effectively than rTMS alone or no treatment.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Active Control
Group I: rTMS+iVCTExperimental Treatment1 Intervention
Group II: rTMSActive Control1 Intervention
Group III: Standard TreatmentActive Control1 Intervention

rTMS is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as rTMS for:
🇪🇺
Approved in European Union as rTMS for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Central Arkansas Veterans Healthcare System

Lead Sponsor

Trials
24
Recruited
343,000+

Published Research Related to This Trial

Repetitive transcranial magnetic stimulation (rTMS) may significantly improve global cognitive function and memory in patients with mild cognitive impairment (MCI), based on a meta-analysis of nine studies involving 369 patients.
While rTMS shows promise for cognitive enhancement, it is associated with a higher rate of mild adverse effects compared to control groups, indicating that while generally safe, monitoring for side effects is important.
Repetitive Transcranial Magnetic Stimulation for Improving Cognitive Function in Patients With Mild Cognitive Impairment: A Systematic Review.Jiang, L., Cui, H., Zhang, C., et al.[2021]
Repetitive transcranial magnetic stimulation (rTMS) is a promising non-invasive brain stimulation technique that can enhance brain excitability and potentially improve conditions like stroke, Parkinson's disease, and depression, as discussed in a 2010 symposium with insights from both animal studies and small clinical trials.
While there is significant interest and some signs of therapeutic success with rTMS, the current models explaining its effects may need refinement to fully understand the underlying mechanisms and outcomes observed in various studies.
Brain stimulation and brain repair--rTMS: from animal experiment to clinical trials--what do we know?Platz, T., Rothwell, JC.[2013]
Repetitive transcranial magnetic stimulation (rTMS) significantly improves cognitive function in patients with mild cognitive impairment (MCI) and early Alzheimer's Disease (AD), with a mean effect size of 1.17 based on a meta-analysis of 12 studies involving 438 participants.
The most effective rTMS protocol involved 10 Hz frequency and stimulation of the dorsolateral prefrontal cortex (DLPFC) for 20 sessions, showing lasting cognitive benefits for up to one month after treatment, particularly for patients with MCI.
Cognitive Enhancement of Repetitive Transcranial Magnetic Stimulation in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease: A Systematic Review and Meta-Analysis.Xie, Y., Li, Y., Nie, L., et al.[2021]

Citations

Repetitive Transcranial Magnetic Stimulation (rTMS) in Mild ...The results of the reviewed studies suggested that rTMS in MCI patients is safe and effective for enhancing cognitive functions, thus making it a potential ...
The effects of repetitive transcranial magnetic and ...The results suggest that both rTMS and tDCS improved memory functions in patients with MCI compared with sham stimulation, but the efficacy of ...
Effectiveness of Repetitive Transcranial Magnetic...The study found that active rTMS led to significant improvement in MMSE scores in people with MCI and early AD.
Efficacy and safety of transcranial magnetic stimulation on ...The reviewed studies provide favorable evidence of improved cognition with TMS across all groups with cognitive impairment.
5.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/34764859/
Effects of Repetitive Transcranial Magnetic Stimulation in ...This study shows that rTMS can improve cognitive function in patients with MCI, especially when applied at high frequency, multi-site, and for a prolonged ...
Transcranial magnetic stimulationTranscranial magnetic stimulation (TMS) is a procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of major depression.
Efficacy and Safety of Transcranial Magnetic Stimulation on ...TMS was safe and well tolerated with infrequent serious adverse events. Keywords: cognition, dementia, meta-analysis, MCI, mild cognitive ...
Repeated Transcranial Magnetic Stimulation in the Elderly ...This study is a randomized controlled trial. We randomly assigned 30 patients with mild cognitive impairment or dementia to the high-frequency transcranial ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security